A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Select Advanced Or Metastatic Solid Tumors With A Smarca4 Mutation
-
Age: Between 18 Year(s) - 100 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
To participate in the study the following conditions must be met:- 1) Patients must have cancer that has spread or come back and is confirmed by a tissue sample. The cancer must have a specific genetic change called "loss of SMARCA4" which can be caused by mutations or deletions
- 2) Participants must either have their cancer get worse after receiving the usual medical treatment, or they cannot receive the usual medical treatment
- 3) Participant must be willing and able to give a sample of their tumor tissue (either stored or a new sample if stored tissue is not available) for testing the SMARCA2 and SMARCA4 proteins and other markers
You may not be eligible for this study if the following are true:
-
You will not be able to participate in the study if you have had:
- 1) A medical or mental health condition or a laboratory result that may make it risky for them to take part in the study or could make it hard to understand the study results
- 2) A solid tumor that has both a SMARCA4 mutation or loss of protein expression and a known SMARCA2 mutation or loss of protein expression
- 3) A heart condition that is important or not well managed
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.